Celadon Pharmaceuticals Financial Health

Short Term Liabilities: CEL's short term assets (£9.8M) exceed its short term liabilities (£1.4M).

Long Term Liabilities: CEL's short term assets (£9.8M) exceed its long term liabilities (£4.4M).

Debt Level: CEL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CEL's debt to equity ratio has reduced over the past 5 years.

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CEL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CEL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 98.9% each year.

• Healthy companies in the Pharmaceuticals & Biotech industry.